文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

异氟烷与丙泊酚在急性低氧性呼吸衰竭有创通气患者镇静中的比较:一项随机对照试验的事前假设亚组研究

Isoflurane vs. propofol for sedation in invasively ventilated patients with acute hypoxemic respiratory failure: an a priori hypothesis substudy of a randomized controlled trial.
PubMed 文献 · Ann Intensive Care · 2022-12-20
一句话结论在急性低氧性呼吸衰竭有创通气患者中,异氟烷吸入镇静最长48小时与丙泊酚静脉镇静相比未改善氧合。

该研究为Sedaconda多中心随机对照试验的事前假设亚组分析,纳入基线PaO2/FiO2 ≤ 300 mmHg的有创机械通气患者162例,随机接受异氟烷或丙泊酚镇静48小时。主要终点为基线至镇静结束的PaO2/FiO2变化,异氟烷组从199 ± 58升至219 ± 76 mmHg(n=70),丙泊酚组从202 ± 62升至236 ± 77 mmHg(n=89),组间无显著差异(p=0.185)。在PaO2/FiO2 ≤ 200 mmHg亚组中,异氟烷组从152 ± 33升至186 ± 54 mmHg(n=37),丙泊酚组从150 ± 38升至214 ± 85 mmHg(n=45),差异有统计学意义(p=0.029),但第7天两组PaO2/FiO2无显著差异(p=0.933)。两组PaCO2、pH、潮气量、30天死亡率及无呼吸机天数均无显著差异。

要点

  • 在PaO2/FiO2 ≤ 300 mmHg的急性低氧性呼吸衰竭患者中,异氟烷镇静48小时与丙泊酚相比未改善氧合(p=0.185)。
  • PaO2/FiO2 ≤ 200 mmHg亚组中,丙泊酚组氧合改善更明显(p=0.029),但第7天两组无显著差异(p=0.933)。
  • 两组PaCO2、pH、潮气量、30天死亡率及无呼吸机天数均无显著组间差异。
  • 该研究为Sedaconda试验的事前假设亚组分析,样本量162例,结果不支持异氟烷用于改善急性低氧性呼吸衰竭氧合。

适用人群与场景

  • 纳入Sedaconda试验中基线PaO2/FiO2 ≤ 300 mmHg的有创机械通气患者(n=162)。
  • 亚组分析纳入基线PaO2/FiO2 ≤ 200 mmHg的患者(n=82)。

诊断标准与关键阈值

  • 急性低氧性呼吸衰竭定义为基线PaO2/FiO2 ≤ 300 mmHg。
  • 亚组分析界值为PaO2/FiO2 ≤ 200 mmHg。

处置流程与药物剂量

  • 异氟烷吸入镇静或丙泊酚静脉镇静,持续时间48小时。

研究设计与关键结果

  • 研究类型:多中心随机对照试验(Sedaconda试验)的事前假设亚组分析;样本量:162例(异氟烷组n=70,丙泊酚组n=89)。
  • 主要终点:基线至镇静结束(48小时)PaO2/FiO2变化,异氟烷组199 ± 58升至219 ± 76 mmHg,丙泊酚组202 ± 62升至236 ± 77 mmHg,p=0.185。
  • 第7天PaO2/FiO2:异氟烷组210 ± 79 mmHg(n=41),丙泊酚组185 ± 87 mmHg(n=44),p=0.411。
  • 亚组(PaO2/FiO2 ≤ 200 mmHg):基线至镇静结束PaO2/FiO2变化,异氟烷组152 ± 33升至186 ± 54 mmHg(n=37),丙泊酚组150 ± 38升至214 ± 85 mmHg(n=45),p=0.029。
  • 亚组第7天PaO2/FiO2:异氟烷组198 ± 69 mmHg(n=20),丙泊酚组174 ± 106 mmHg(n=20),p=0.933。
  • 全研究人群及亚组中,PaCO2、pH、潮气量、30天死亡率及无呼吸机天数均无显著组间差异。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验的事前假设亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急性低氧性呼吸衰竭有创通气患者,异氟烷吸入镇静最长48小时与丙泊酚相比未改善氧合,不支持以改善氧合为目的选择异氟烷镇静。

指南或共识出处

  • Sedaconda试验(EudraCT 2016-004551-67);本亚组研究注册于德国临床试验注册中心(DRKS00018959)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute hypoxemic respiratory failure (AHRF) is a leading concern in critically ill patients. Experimental and clinical data suggest that early sedation with volatile anesthestics may improve arterial oxygenation and reduce the plasma and alveolar levels of markers of alveolar epithelial injury and of proinflammatory cytokines.

METHODS: An a priori hypothesis substudy of a multicenter randomized controlled trial (The Sedaconda trial, EUDRA CT Number 2016-004551-67). In the Sedaconda trial, 301 patients on invasive mechanical ventilation were randomized to 48 h of sedation with isoflurane or propofol in a 1:1 ratio. For the present substudy, patients with a ratio of arterial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2), PaO2/FiO2, of ≤ 300 mmHg at baseline were included (n = 162). The primary endpoint was the change in PaO2/FiO2 between baseline and the end of study sedation. A subgroup analysis in patients with PaO2/FiO2 ≤ 200 mmHg was performed (n = 82).

RESULTS: Between baseline and the end of study sedation (48 h), oxygenation improved to a similar extent in the isoflurane vs. the propofol group (isoflurane: 199 ± 58 to 219 ± 76 mmHg (n = 70), propofol: 202 ± 62 to 236 ± 77 mmHg (n = 89); p = 0.185). On day seven after randomization, PaO2/FiO2 was 210 ± 79 mmHg in the isoflurane group (n = 41) and 185 ± 87 mmHg in the propofol group (n = 44; p = 0.411). In the subgroup of patients with PaO2/FiO2 ≤ 200 mmHg, PaO2/FiO2 increase between baseline and end of study sedation was 152 ± 33 to 186 ± 54 mmHg for isoflurane (n = 37), and 150 ± 38 to 214 ± 85 mmHg for propofol (n = 45; p = 0.029). On day seven, PaO2/FiO2 was 198 ± 69 mmHg in patients randomized to isoflurane (n = 20) and 174 ± 106 mmHg in patients randomized to propofol (n = 20; p = 0.933). Both for the whole study population and for the subgroup with PaO2/FiO2 ≤ 200 mmHg, no significant between-group differences were observed for PaCO2, pH and tidal volume as well as 30-day mortality and ventilator-free days alive.

CONCLUSIONS: In patients with AHRF, inhaled sedation with isoflurane for a duration of up to 48 h did not lead to improved oxygenation in comparison to intravenous sedation with propofol. Trial registration The main study was registered in the European Medicines Agency's EU Clinical Trial register (EudraCT), 2016-004551-67, before including the first patient. The present substudy was registered at German Clinical Trials Register (DRKS, ID: DRKS00018959) on January 7th, 2020, before opening the main study data base and obtaining access to study results.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Becher T, Meiser A, Guenther U, et al. Isoflurane vs. propofol for sedation in invasively ventilated patients with acute hypoxemic respiratory failure: an a priori hypothesis substudy of a randomized controlled trial. Ann Intensive Care. 2022. PMID: 36538243. doi:10.1186/s13613-022-01090-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。